Key result
Oral administration of the ovalbumin-derived peptide RADHPF at /kg lowered systolic blood pressure in spontaneously hypertensive rats.
Why the study?
Does the ovalbumin-derived peptide RADHPF reduce systolic blood pressure and induce vasorelaxation in spontaneously hypertensive rats?
Does the ovalbumin-derived peptide RADHPF reduce systolic blood pressure and induce vasorelaxation in spontaneously hypertensive rats?
Answers are grounded in this paper and cite their sources.
The novel ovalbumin-derived peptide RADHPF demonstrates nitric oxide-mediated vasorelaxant properties and lowers systolic blood pressure in a hypertensive rat model, suggesting potential as an anti-hypertensive agent.
In this report, we deal with the isolation of a novel vasorelaxing peptide from a chymotryptic digest of ovalbumin and its vasorelaxing activities. This peptide is composed of Arg-Ala-Asp-His-Pro-Phe (RADHPF) in its sequence, corresponding to residues 359-364 of ovalbumin. This peptide (30-300 microM) exerted a dose-dependent vasodilation in an isolated mesenteric artery from a spontaneously hypertensive rat which was pre-constricted by phenylephrine, besides the relaxation being endothelium-dependent. It is noteworthy that the nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester inhibited this relaxation, implying involvement of nitric oxide in its mechanism of action. Following oral administration of RADHPF at a dose of 10 mg/kg, the systolic blood pressure in a spontaneously hypertensive rat was significantly lowered.
No takes yet. Share an insight, caveat, or question.
Matoba et al. (1999) studied Hypertension. RADHPF (ovalbumin-derived peptide) was evaluated on Vasodilation and systolic blood pressure. Oral administration of the ovalbumin-derived peptide RADHPF at /kg lowered systolic blood pressure in spontaneously hypertensive rats.
Synapse has enriched 10 related papers. Consider them for comparative context: